Kangzhi Pharmaceutical Co., Ltd.

Announcement on the Company Obtaining the Drug Registration Certificate

Announcement on Participation in the Hainan Region Listed Companies 2025 Annual Report Performance Briefing and Investor Online Collective Reception Day Activities

Announcement on the Correction of Previous Accounting Errors and Retrospective Adjustments

Financial Statements and Notes After Correction of Previous Accounting Errors

Kangzhi 2023 Audit Report (Correction)

Special Verification Report on the Correction of Previous Accounting Errors of Kangzhi Pharmaceutical Co., Ltd.

Announcement on Confirming the Compensation Plans for Directors and Senior Management for 2025 and 2026

Announcement on Uncovered Losses Reaching One-Third of the Total Paid-in Capital

Announcement on the Provision for Asset Impairment for the Year 2025

2026 Investor Relations Management Plan

Report on the Performance of the Audit Committee of the Board of Directors of Kangzhi Pharmaceutical Co., Ltd. for 2025

2025 Independent Director Work Report (Tang Linyan)

2025 Independent Director Work Report (Zheng Huanxue)

2025 Independent Director Work Report (Wu Qinghe)

2025 Independent Director Work Report (Zhang Jicheng - Resigned)

2025 Independent Director Work Report (Fang Canhui)

Kangzhi Pharmaceutical 2025 Sustainable Development Report

2025 Internal Control Audit Report

Announcement of the 2025 Internal Control Self-Evaluation Report and Related Opinions

Accounting Policy, Accounting Estimate Changes, and Accounting Error Management System

Rectification Report on the Decision of Hainan Securities Regulatory Bureau to Order the Company to Correct

Announcement on Expected Daily Related Transactions for the Year 2026

Announcement on Matters Related to Applying for Comprehensive Credit Limits from Financial Institutions

Announcement of Resolutions from the Third Meeting of the Seventh Board of Directors

Announcement on the Company's Profit Distribution Plan for the Year 2025

Q1 2026 Report

Special Explanation by the Board of Directors on Matters Involved in the Unqualified Internal Control Audit Report with Emphasis Paragraph

Special Verification Report on the Deduction of Operating Income for Kangzhi Pharmaceutical Co., Ltd. for 2025

Special Audit Report on Non-Operating Fund Occupation and Settlement Situation of Kangzhi Pharmaceutical Co., Ltd.

Evaluation Report on the Performance of the Accounting Firm for 2025

Report by the Audit Committee of Kangzhi Pharmaceutical Co., Ltd. on the Evaluation of the Performance of the Annual Audit Firm for 2024 and the Fulfillment of Supervisory Responsibilities

Special Audit Report on Non-Operating Fund Occupation and Other Related Fund Transactions of Kangzhi Pharmaceutical Co., Ltd.

Special Report on the Self-Examination of Independent Directors' Independence by the Board of Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Announcement on Receiving the Decision of Hainan Securities Regulatory Bureau to Order the Company to Correct

Announcement on the Wholly-Owned Subsidiary Being Selected in the National Centralized Procurement Drug Agreement Period Expiration Variety Continuation Procurement